ArticleJournal of thoracic disease2026
Efficacy and safety of radiotherapy following chemoimmunotherapy in extensive-stage small cell lung cancer: a retrospective comparative cohort study of consolidation versus salvage indications.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemoimmunotherapy (CIT) is the standard first-line regimen for extensive-stage small cell lung cancer (ES-SCLC), based on phase 3 trials such as IMpower133 and CASPIAN. However, these pivotal trials excluded thoracic radiotherapy (RT), and current guidelines lack clear recommendations regarding the addition of RT to CIT. Consequently, it remains uncertain whether adding local RT following first-line CIT enhances survival or distant metastasis control without exacerbating toxicity. This real-world study aimed to assess the efficacy and safety of adding local RT to first-line CIT in ES-SCLC, emphasizing the impact of RT timing (consolidation Methods: We retrospectively analyzed 132 ES-SCLC patients treated with first-line CIT from January 2019 to December 2024 at Xuzhou Medical University Affiliated Hospital. Inclusion criteria included histologically confirmed ES-SCLC, Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2, and at least two cycles of first-line CIT. Patients were categorized into two groups: CIT plus RT (n=73) and CIT alone (non-RT) (n=59). Baseline characteristics, tumor response, and treatment-related adverse events (AEs) were compared between groups using Chi-squared tests. Progression-free survival (PFS), primary tumor PFS (PFS-PT), distant metastasis PFS (PFS-DM), and overall survival (OS) were analyzed using Kaplan-Meier curves and log-rank tests. Cox proportional hazards models were used for univariate and multivariate analyses. Results: Baseline characteristics were largely balanced, except for significantly higher baseline brain (28.8% Conclusions: This retrospective study found that adding local RT to first-line CIT significantly improved OS and primary tumor control in ES-SCLC without increasing AEs. RT may serve as an independent favorable prognostic factor, and consolidation timing appears crucial. These findings generate hypotheses requiring prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.